Flash Finance

Vimta Labs LimitedVIMTALABSCorporate

Healthcare Research, Analytics & Technology Latest results: Dec 2024 13 quarters of data
Consolidated Standalone
₹522.45
MCap ₹2,335 Cr · P/E 38.0
Vimta Labs Limited — Stock analysis & AI research Vimta Labs Limited — Seasonality — best & worst months Vimta Labs Limited — Technical indicators & charts Vimta Labs Limited — Technical setup — score, trend, support & resistance Vimta Labs Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 Low Debt Stocks📋 Quality Stocks📋 Quality Stocks Near 52-Week Low 📈 RSI Oversold Stocks📈 Lowest Technical Score 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹90 Cr
Sales · Dec 2024
+10.1% YoY
₹33 Cr
Operating Profit · Dec 2024
+51.5% YoY
36.8%
OPM % · Dec 2024
+37.8% YoY
₹21 Cr
Net Profit · Dec 2024
+112.2% YoY
₹9.65
EPS · Dec 2024
+111.2% YoY

📝 Vimta Labs Limited — results explained

Quarter ended December 2024 (Q3 FY25)

Vimta Labs Limited reported revenue of ₹90 crore for the quarter ended December 2024 (Q3 FY25), up 10.1% from ₹82 crore in the same quarter last year, and up 6.1% sequentially over the September 2024 quarter.

Net profit rose 112.2% year-on-year to ₹21 crore, from ₹10 crore. Earnings per share (EPS) came in at ₹9.65.

Operating profit stood at ₹33 crore — an operating margin (OPM) of 36.8%, compared with 26.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY25, Vimta Labs Limited posted revenue of ₹256 crore, a decline of 19.4% over FY24, with a net profit of ₹49 crore (up 19.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹336 crore with a net profit of ₹61 crore.

Valuation snapshot

At the current price of ₹522.45, VIMTALABS has a market capitalisation of ₹2,335 crore and a trailing P/E of about 38.0.

Within the Healthcare Research, Analytics & Technology industry, it is the 3rd-largest of the 10 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 35.67%, foreign institutional investors (FIIs) 4.42%, domestic institutional investors (DIIs) 0.37%, public shareholders 59.55% of Vimta Labs Limited.

Promoter holding slipped from 35.85% to 35.67% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,335 Cr
Current Price ?
₹522.5
P/E ?
38.04above ind
Industry P/E ?
35.60
P/B ?
5.11
P/S ?
6.95
P/FCF ?
49.67
Enterprise Value ?
₹2,338 Cr
EV/EBITDA ?
20.89
PEG ?
1.59
Earnings Yield ?
3.3%
Dividend Yield ?
0.38%
Profitability & Returns
Sales (TTM) ?
₹336 Cr
OPM ?
33.3%
Profit after tax (TTM) ?
₹61 Cr
EPS (TTM) ?
₹13.73
ROCE ?
25.0%
ROE ?
13.4%
ROA ?
10.9%
Growth
Sales — latest qtr ?
₹90 Cr
PAT — latest qtr ?
₹21 Cr
YoY qtr sales growth ?
10.1%
YoY qtr profit growth ?
112.2%
Sales growth (3y) ?
15%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
24%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹3 Cr
Debt to Equity ?
0.01
Interest Coverage ?
41.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
35.67%
Change in promoter holding ?
-1.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.6%
Return 6 months ?
9.2%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024 YoY % QoQ %
Sales 67747980778283738280828590 +10.1% +6.1%
Operating Profit 21232425212425162224253033 +51.5% +10.6%
Other Income 1011111210116 +582.5% +793.0%
Interest 0111100111001 +9.0% +43.8%
Depreciation 67788889988810 +12.8% +18.3%
Profit Before Tax 1516171814171681416172229 +113.2% +31.6%
Net Profit 1212121310131261012121521 +112.2% +41.0%
EPS 2.642.682.722.992.325.735.512.854.575.585.546.889.65 +111.2% +40.3%
OPM % 31.3% 31.1% 30.4% 31.2% 27.3% 29.5% 29.5% 21.6% 26.7% 30.6% 30.0% 35.3% 36.8% +37.8% +4.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY24 FY25 TTM YoY %
Sales ₹318 Cr ₹256 Cr ₹336 Cr -19.4%
Operating Profit ₹87 Cr ₹88 Cr ₹112 Cr +0.8%
OPM % 27.27% 34.13% 33.30% +25.2%
NPM % 12.89% 19.12% 18.26% +48.3%
Other Income ₹4 Cr ₹7 Cr ₹8 Cr +86.7%
Depreciation ₹34 Cr ₹26 Cr ₹34 Cr -23.1%
Interest ₹2 Cr ₹1 Cr ₹2 Cr -30.9%
EBIT ₹53 Cr ₹61 Cr ₹78 Cr +16.4%
PBT ₹54 Cr ₹67 Cr ₹83 Cr +23.4%
Tax ₹13 Cr ₹16 Cr ₹20 Cr +21.9%
Net Profit ₹41 Cr ₹49 Cr ₹61 Cr +19.5%
EPS ₹18.51 ₹22.07 ₹27.65 +19.2%
Material Cost ₹76 Cr ₹58 Cr ₹75 Cr -24.5%
Employee Cost ₹99 Cr ₹72 Cr ₹96 Cr -27.7%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 4449 +125.0%
Reserves 276310374448 +19.8%
Borrowings 151993 -66.7%
Other Liabilities 656179102 +29.1%
Total Liabilities 360394467562 +20.3%
Fixed Assets 168166230305 +32.6%
CWIP 12593818 -52.6%
Investments 6002 —
Other Assets 174170198237 +19.7%
Total Assets 360394467562 +20.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 876194147 +56.4%
Cash from Investing Activity -57-76-76-130 -71.1%
Cash from Financing Activity -11-2-16-10 +37.5%
Net Cash Flow 19-1727 +250.0%
Free Cash Flow 37-141747 +176.5%
CFO/OP 106%81%95%121% +27.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 9311011395 -15.9%
Inventory Days 195260210203 -3.3%
Days Payable 124878879 -10.2%
Cash Conversion Cycle 164283235219 -6.8%
Working Capital Days 78989683 -13.5%
ROCE % 24%20%25%25% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 36.67%35.99%35.89%35.85%35.67% -0.5%
FIIs 3.49%4.33%4.59%4.89%4.42% -9.6%
DIIs 1.42%0.87%0.11%0.13%0.37% +184.6%
Public 58.42%58.80%59.40%59.12%59.55% +0.7%
No. of Shareholders 30,82955,93354,46751,62350,190 -2.8%

⚖️ Peer comparison

Industry: Healthcare Research, Analytics & Technology · 10 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 INDGN Indegene ₹597.05 14,377 35.8 3,812 401 16.7% 10.5% 23.6% -1.5% 39.7% -0.2%
2 SUVEN Suven Life ₹286.25 8,088 — 9 -353 -3955.0% -3815.2% 6.9% -71.9% 114.3% -148.5%
3 VIMTALABS Vimta Labs ₹637.20 2,847 35.7 419 80 34.4% 19.1% 18.0% 19.5% 11.3% 10.7%
4 FABTECH Fabtech Technologies ₹145.66 647 44.8 364 14 2.4% 4.0% — — 10.3% 168.7%
5 526853 Bilcare Ltd-$ ₹61.25 215 — 773 -6 9.1% -0.8% -6.9% 36.7% 21.2% 253.4%
6 TAKE Take Solutions ₹12.69 186 14.6 85 13 -2.0% 15.2% — -71.0% — 216.8%
7 536565 Novelix Pharmaceuticals ₹19.88 181 13.2 147 4 3.1% 2.5% 330.7% 2218.2% 65.2% 971.7%
8 538837 Jeevan Scientific ₹50.96 178 22.6 71 5 20.5% 7.2% 31.4% 1371.4% 107.7% 127.0%
9 543309 Adeshwar Meditex ₹27.50 24 31.2 56 1 4.9% 2.2% — — -30.4% -60.4%
10 540729 Vanta Bioscience ₹51.45 15 333.1 2 0 55.8% 6.1% — — 357.6% 240.9%
❓ Frequently asked questions
What was Vimta Labs Limited's revenue in Q3 FY25?
Vimta Labs Limited reported revenue of ₹90 crore for the quarter ended December 2024 (Q3 FY25), up 10.1% from ₹82 crore in the same quarter last year, and up 6.1% sequentially over the September 2024 quarter.
What was Vimta Labs Limited's net profit in Q3 FY25?
Net profit rose 112.2% year-on-year to ₹21 crore, from ₹10 crore. Earnings per share (EPS) came in at ₹9.65.
What is VIMTALABS's market capitalisation and P/E ratio?
At the current price of ₹522.45, VIMTALABS has a market capitalisation of ₹2,335 crore and a trailing P/E of about 38.0.
Who owns Vimta Labs Limited? (shareholding pattern)
As of Jun 2026, promoters held 35.67%, foreign institutional investors (FIIs) 4.42%, domestic institutional investors (DIIs) 0.37%, public shareholders 59.55% of Vimta Labs Limited.
TTM ends 2024-12-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI